Record overview
Status and phase
Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1, PHASE2
Sponsor: BeiGene
Condition: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
NCT05609370
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: primary_completion_date_past_signal | long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.